- Home
- SKIN vs IBIO Comparison
SKIN vs IBIO Comparison
Compare SKIN & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.69
HOLD
Current Price
$1.45
Company Overview
Basic Information| Metric | SKIN | IBIO |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 83.5M |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SKIN | IBIO |
|---|---|---|
| Price | $0.69 | $1.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $2.03 | ★ $4.75 |
| AVG Volume (30 Days) | 494.9K | ★ 721.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 55.56 | ★ 73.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $300,790,000.00 | N/A |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $0.77 |
| 52 Week High | $2.69 | $3.82 |
Technical Indicators
Market Signals| Indicator | SKIN | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 51.53 |
| Support Level | $0.59 | $1.41 |
| Resistance Level | $0.78 | $1.54 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 56.43 | 63.50 |
Price Performance
Historical Comparison SKIN
IBIO
About SKIN The Beauty Health Company
SkinHealth Systems Inc is a world-wide medical aesthetics company delivering an integrated ecosystem of clinically validated solutions designed to help consumers achieve superior skin health and support the success of providers. Its brands are Hydrafacial and SkinStylus.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.